WO2004100993A1 - 眼科用組成物 - Google Patents
眼科用組成物 Download PDFInfo
- Publication number
- WO2004100993A1 WO2004100993A1 PCT/JP2004/005837 JP2004005837W WO2004100993A1 WO 2004100993 A1 WO2004100993 A1 WO 2004100993A1 JP 2004005837 W JP2004005837 W JP 2004005837W WO 2004100993 A1 WO2004100993 A1 WO 2004100993A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ophthalmic composition
- molecular weight
- composition according
- hydroxypropylmethylcellulose
- feeling
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Definitions
- the present invention relates to an ophthalmic composition, and particularly to an ophthalmic composition having an excellent feeling in use, which is advantageously used as an ophthalmic solution for contact lenses, a liquid solution for contact lenses, and the like.
- an artificial tear type ophthalmic solution is generally widely used, but such an ophthalmic solution has been generally used.
- the artificial tear-type ophthalmic solution has a moisturizing effect due to tearing off and foreign substances are washed away to reduce dryness and discomfort. Minutes are known to pass through the lacrimal passages in a relatively short time due to blinking, and are washed away, which has a problem of poor sustainability of the effect.
- a thickening agent or the like is blended with the greasy artificial tear-type ophthalmic solution that maintains the effect of reducing the feeling of dryness, etc., to improve wettability or to provide an ophthalmic solution on the cornea.
- some measures have been taken to extend the residence time, sufficient effects have not been obtained.
- the viscosity of the solution becomes too high, and the increase in the viscosity causes the image to be distorted or blurred, resulting in unstable visual acuity. In other words, discomfort such as blurring may be caused.
- Patent Document 1 a composition for soft contact lenses containing hydroxypropyl methylcellulose having a weight average molecular weight of 50,000 to 400,000 used as a thickener, and thereby a protein or the like for soft contact lenses has been proposed.
- Hydroxypropyl methylcellulose with a relatively high weight-average molecular weight is used because hydroxypropyl methylcellulose has a relatively high weight-average molecular weight.
- the cleaning effect is poor, as it is difficult to penetrate dirt such as eye oil attached to the lens.Even if the concentration is lowered to suppress the increase in viscosity, discomfort such as unstable visual acuity may occur after instillation. That was the problem.
- Patent Document 1 JP-A-2002-322048
- the present invention has been made in the background of vigorous circumstances, and the problem to be solved is to provide a good moisturizing effect on the eyes while preventing instability such as visual acuity instability.
- An object of the present invention is to provide an ophthalmic composition which can advantageously prevent the occurrence of a pleasant sensation and realize a more excellent feeling in use.
- the inventors of the present invention have conducted intensive studies to solve such problems, and as a result, the occurrence of discomfort such as instability of visual acuity was caused by the hydroxypropylmethyl cellulose molecule contained in the ophthalmic composition. It was presumed to be due to the entanglement between them. As a result of further study, among the hydroxypropyl methylcellulose, those having a molecular weight (weight average molecular weight) smaller than the entanglement critical molecular weight at 3 w / w% concentration, among others, were adopted.
- the present invention has been completed based on knowledge such as power, Entanglement when hydroxypropylmethylcellulose concentration is 3w / w%, use hydroxypropylmethylcellulose having a molecular weight less than the critical molecular weight, dissolve it in aqueous medium and have kinematic viscosity at 20 ° C. Is 2 mm 2 / s or less.
- the above-mentioned ophthalmic composition is sufficiently provided with safety for eyes and has excellent lens adaptability. , Eye drops, particularly eye drops for contact lenses.
- the above-mentioned ophthalmic composition comprises a contact lens cleaning solution, a contact lens storage solution, a contact lens sterilizing solution, a contact lens rinsing solution, Also, it can be advantageously used as a contact lens solution such as a multi-purpose solution.
- the hydroxymethyl pyrmethylcellulose preferably has a methoxyl group substitution degree of 28 to 30% by weight.
- the hydroxypropoxyl group substitution degree of hydroxypropyl methylcellulose is preferably 7 to 12% by weight.
- the hydroxypropyl methylcellulose is desirably contained at a ratio of 0.05 w / w% or more, and 0.8 w / w%. It is desirable for the content to be contained at a ratio of / w% or less.
- Power Q According to another preferred embodiment of the ophthalmic composition according to the present invention, isotonic agents, chelating agents, buffers, fresheners, preservatives, bactericides and surfactants. At least one of the agents may also be included.
- the pH is 5.3.
- the osmotic pressure S is 200 and 400 m ⁇ sm / kg.
- hydroxypropyl methylcellulose having a molecular weight of less than the entanglement critical molecular weight is dissolved and contained as one of the components constituting the ophthalmic composition. While being squeezed, the kinematic viscosity is from a predetermined value or less, in the ophthalmic composition, The intertwining of the molecules of the loin is extremely advantageously prevented. As a result, the surface active effect of the hydroxypropylmethylcellulose molecule is advantageously exhibited without being hindered, and it is possible to effectively remove dirt such as eye oil and mucoid adhering to the cornea and the lens outside the contour.
- hydroxypropyl methylcellulose incorporated according to the present invention can be applied to the eyes and contact lenses similarly to the relatively high molecular weight hydroxypropylmethylcellulose, which is also conventionally used. It does not have any adverse effects and has excellent safety and lens compatibility.
- the above-mentioned ophthalmic composition when used as an eye drop and a predetermined amount thereof is instilled, symptoms such as discomfort and dryness of the eyes can be improved.
- symptoms such as discomfort and dryness of the eyes can be improved.
- the lens surface is advantageously hydrophilized, water wettability is improved, and fogging of the lens may occur. It is effectively prevented, and a more excellent feeling of use and wearing of the lens can be realized.
- the ophthalmic composition according to the present invention When the ophthalmic composition according to the present invention is used as a liquid preparation for contact lenses, dirt attached to the contact lens surface is extremely effectively removed, and the water wettability of the contact lens surface is reduced to hydroxypropyl methylcellulose. Thus, the occurrence of clouding of the lens and the like can be effectively suppressed. If a contact lens treated with such a solution is worn, various symptoms such as a foreign body sensation, irritation to the eyes, discomfort such as difficulty in seeing, and a feeling of dryness during wearing are advantageous. Will be suppressed.
- the powerful ophthalmic composition according to the present invention mainly comprises an aqueous medium, in which hydroxypropylmethylcellulose having a specific molecular weight is contained as an essential component, and at 20 ° C.
- a desired effect can be realized, which has a great feature.
- hydroxypropyl methyl cellulose used as an essential component in the present invention is characterized in that a part of hydrogen of a hydroxyl group of cellulose is a methyl group (1-CH) ⁇ hydroxypropyl group.
- the “entanglement critical molecular weight” described above is a molecular weight at a critical point at which hydroxypropyl methylcellulose molecules become entangled with each other and the kinematic viscosity changes rapidly, and the degree of polymerization (molecular weight) Are prepared by preparing hydroxypropyl methylcellulose having different kinetic viscosities and measuring their kinematic viscosities under conditions of a predetermined concentration and temperature. Under the temperature condition of 20 ° C. More specifically, FIG. 1 shows a logarithmic graph showing the relationship between the weight average molecular weight of hydroxypropyl methylcellulose and the kinematic viscosity in a 3 w / w% aqueous solution obtained in Examples described later.
- the kinetic viscosity sharply rises due to the entanglement of hydroxypropylmethyl cellulose molecules at a certain molecular weight.
- the molecular weight at this critical point is the entanglement critical molecular weight, which is about 50,000 in FIG.
- the entanglement critical molecular weight also varies depending on the degree of substitution between the methoxyl group (-OCH) and the hydroxypropoxyl group (one OCH CHOHCH) of hydroxypropylmethylcellulose.
- hydroxypropylmethylcellulose having a molecular weight smaller than the entanglement critical molecular weight is used in the present invention, the degree of substitution between the methoxycinole group and the hydroxypropoxyl group, which is advantageously used in the present invention, is too low. In such a case, the ratio of hydrophobic groups in the hydroxypropyl methylcellulose molecule is reduced, which may result in an extremely low surfactant activity, which may make it impossible to sufficiently exert the cleaning effect.
- Degree of xyl substitution ⁇ If the degree of substitution of hydroxypropoxynole group is too high, the proportion of hydrophobic groups in the hydroxypropylmethylcellulose molecule increases, resulting in excessively high hydrophobicity and clouding of the contact lens surface. And the feeling of use becomes worse Among xypropylmethylcellulose, those having a methoxyl group substitution degree of 2830% by weight or hydroxypropoxyl group substitution degree of 712% by weight are more preferably employed.
- the above “degree of methoxyl group substitution” refers to the weight ratio of methoxyl group (or hydroxypropoxyl group) in hydroxypropylmethylcellulose molecule. It is expressed as a percentage (% by weight), and from this substitution degree, the average number of substituted hydroxyl groups per glucose ring unit of hydroxypropylmethylcellulose can be calculated. For example, there are three hydroxyl groups per glucose ring unit of hydroxypropylmethylcellulose. When the methoxyl group substitution degree is 30% by weight, the average of the three hydroxyl groups is 2.03. When the number of hydroxy groups was substituted with a methoxy group, and the degree of hydroxypropoxy group substitution was 12% by weight, an average of 0.34 hydroxyl groups were replaced with a hydroxypropoxy group.
- Such hydroxypropylmethylcellulose is commercially available, and is, for example, Metrolose TC-5E (weight average molecular weight: 20,000, methoxyl) manufactured by Shin-Etsu Chemical Co., Ltd. Degree of group substitution: 28-30% by weight, degree of hydroxypropoxyl group substitution: 7-12% by weight, Metrolose TC-1R (weight average molecular weight: 30,000, degree of methoxyl group substitution: 28-30% by weight, hydroxy) Propoxyl group substitution degree: 7 to 12% by weight), and such commercially available products can be appropriately selected and used.
- the ophthalmic composition according to the present invention has a predetermined molecular weight as described above. Is dissolved in an aqueous medium, and its kinematic viscosity is set to 2 mm 2 / s or less at 20 ° C. Therefore, the entanglement of hydroxypropyl methylcellulose molecules in the ophthalmic composition Can be prevented very effectively. For this reason, the hydroxypropyl methylcellulose molecule can move freely in the ophthalmic composition, and the surfactant effect by the hydroxypropinolemethinole cellulose molecule can be advantageously expressed without any inhibition.
- the kinematic viscosity of the ophthalmic composition at 20 ° C. may be 2 mm 2 Even if it is set to less than / s, the usability will not be improved, causing unpleasant sticky feeling ⁇ and unstable visual acuity such as image distortion (so-called blur).
- the lower limit of the molecular weight of hydroxypropylmethylcellulose is not particularly limited, but is preferably such a molecular weight that the viscous action of hydroxypropylmethylcellulose can be advantageously achieved in consideration of economy. .
- the kinetic viscosity of the ophthalmic composition at 20 ° C exceeds 2 mm 2 / s, even if the molecular weight force of the hydroxypropyl methylcellulose is less than the entanglement critical molecular weight as described above, As in the case of using hydroxypropyl methylcellulose having a molecular weight higher than the critical molecular weight, the feeling of use cannot be improved, and uncomfortable stickiness ⁇ and unstable visual acuity such as image distortion (so-called blur) ) Is caused.
- the lower limit of the force and the kinematic viscosity is not particularly limited. However, it is generally desirable that the force is set to 1. Omm 2 Zs or more.
- the ophthalmic composition at 20 ° C In the range where the kinematic viscosity is 2 mm 2 / s or less, the content is appropriately set.However, in order to effectively exhibit the surface active action peculiar to hydroxypropyl methylcellulose, it is necessary to use an ophthalmic composition. It is desirable that the compound be contained at a ratio of 0.05 w / w% or more, preferably 0.1 lw / w% or more. Also, the hydroxypropyl methylcellulose used in the present invention has a molecular weight less than the critical molecular weight for entanglement at a concentration of 3 wZw%. However, the upper limit is preferably 0.8 w / w ° / 0 or less.
- the ophthalmic composition according to the present invention is prepared by adding and dissolving such a specific hydroxypropylmethyl cellulose in an appropriate amount in an appropriate aqueous medium in the same manner as before.
- an isotonic agent used in a general eye drop or a liquid for contact lens use may be used.
- One or two or more of the additional components described below, such as a chelating agent, a buffer, a refreshing agent, a preservative, a bactericide, and a surfactant are appropriately selected, and are usually added. Even if it is added in a proportion, there is no problem.
- such added components have high safety to the living body and are sufficiently ophthalmologically acceptable, and that they have no influence on the shape or physical properties of the contact lens.
- the compound be used within a quantitative range that satisfies such requirements, so that various functions corresponding to the added components can be provided to the ophthalmic composition without inhibiting the effect of the present invention at all. It can be advantageously provided.
- the ophthalmic composition of the present invention in order for the ophthalmic composition of the present invention to advantageously exhibit a disinfecting effect or a bactericidal effect on the eyes and contact lenses, and further exhibit the preservative and preservative effects of the ophthalmic composition.
- An antiseptic or a bactericide having an antiseptic effect or a bactericidal effect is added.
- such antiseptics and bactericides are desired to have an antiseptic or bactericidal effect and excellent compatibility with eyes and contact lenses, as well as those which are unlikely to cause allergies and other obstacles.
- Appropriate ones are selected from various types known for mackerel, and used alone or in combination.
- examples of the preservative include sorbic acid, potassium sorbate, benzoic acid or a salt thereof, ethyl para-hydroxybenzoate, butyl para-hydroxybenzoate, propyl para-oxybenzoate, propyl para-benzoate, methyl para-oxybenzoate, and chloro. Butanol and the like.
- sorbic acid and potassium sorbate can be particularly preferably employed because the influence on the soft contact lens is extremely small. More specifically, sorbic acid and potassium sorbate are anionic and are hardly adsorbed or taken up in the material of soft contact lenses. Allergy can advantageously be avoided.
- examples of the bactericide include quaternary ammonium bactericides such as biguanide bactericides such as polyhexamethylene biguanide (PHMB) and polyquatanium.
- Such preservatives and bactericides are appropriately used, and when they are not added, a single dose type which can be used in one time or a method disclosed in JP-A-2002-80055 is used. As disclosed, it is also possible to use a multi-dose type using a discharge container with a filter in which a membrane filter is attached to the nose portion of the eye drop container.
- the pH value of such an ophthalmic composition can be adjusted to about 5.3-8.5, especially by adding a suitable pH adjuster or buffering agent. It is desirable that the osmotic pressure is adjusted to around 200 to 400 mOsm / kg by adding a tonicity agent, etc. is there.
- pH adjuster sodium hydroxide-hydrochloric acid or the like is used, while the pH of the ophthalmic composition is effectively and ophthalmic within the above-mentioned range.
- a buffering agent for keeping the buffer in a safe range it can be appropriately selected from various conventionally known ones and used.
- acids such as phosphoric acid, boric acid, carboxylic acid, and oxycarboxylic acid, and salts thereof (eg, sodium salt), and Good-Buffer tris (hydroxymethyl) aminoaminomethane (TRIS), bis (2-Hydroxyethyl) iminotris (hydroxymethyl) methane (Bis_Tris), sodium bicarbonate
- TMS Good-Buffer tris (hydroxymethyl) aminoaminomethane
- Bis_Tris bis (2-Hydroxyethyl) iminotris (hydroxymethyl) methane
- the tonicity adjusting agent used for adjusting the osmotic pressure is at least one selected from the group consisting of sodium chloride, potassium chloride, saccharides, sugar alcohols, and polyhydric alcohols or ethers or ester forces thereof.
- the above compounds will generally be used
- contact lenses particularly soft contact lenses, generally have a possibility of depositing or adsorbing calcium and the like as stains from tears, the deposition or adsorption of such calcium or the like may occur.
- a chelating agent will also be advantageously added to the ophthalmic composition that prevents adsorption.
- chelating agents include ethylenediaminetetraacetic acid (EDTA) and salts thereof, such as ethylenediaminetetraacetic acid disodium (EDTA-2Na) and ethylenediaminetetraacetic acid trisodium (EDTA '3Na).
- Menthol, borneol, camphor, geraniol, eucalyptus oil, bergamot oil, wicket oil, etc. for the purpose of giving calories and refreshing feeling when instilling eyes and eliminating foreign body itchiness when wearing contact lenses, etc. It is also possible to add a cooling agent such as heart oil, rose oil or cool mint.
- the ophthalmic composition according to the present invention can exhibit the effect of removing dirt such as eye oils and mucoid (washing effect) by hydroxypropylmethylcellulose more advantageously, and can be used in an aqueous medium.
- various known surfactants may be added or contained.
- the surfactant if it has high safety to the living body and does not affect the contact lens, conventionally known anionic surfactants, nonionic surfactants, amphoteric surfactants, and the like. Any of the surfactants can be employed, and is advantageously added or contained at a concentration that does not impair the effects of the present invention.
- surfactants include, for example, polyoxyethylene-polypropylene propylene block copolymers and derivatives thereof, and polyethylene glycols such as polyonyl ether formaldehyde condensates such as tyloxapol.
- Glycerol fatty acid esters such as reglycol derivatives, sorbitan fatty acid esters such as sorbitan sesquioleate, polyoxyethylene sorbitan monooleate (for example, polysorbate 80), glycerin fatty acid esters such as glyceryl monostearate, polyethylene glycol monostearate, etc.
- Polyethylene glycol fatty acid esters such as polyoxyethylene lauryl ether, polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil, polyoxyethylene alkyl ether carboxylic acids and salts thereof, sucrose fatty acid esters, etc. It will be used advantageously.
- polyoxyethylene-polyoxypropylene block copolymers such as pluronic, pull-mouth nick R, tetronic, tetronic R (commercially available in Germany) are commercially available as nonionic surfactants.
- the viscosity can be adjusted by hydroxypropylmethylcellulose having a specific molecular weight, and various active ingredients can be retained on the cornea or the conjunctival sac for a long time. It is possible to add a thickening agent or a thickening agent other than hydroxypropyl methylcellulose within a quantitative range that does not inhibit the effect of hydroxypropylmethylcellulose, though it is intended to be obtained.
- thickeners examples include various gums such as polysaccharides such as chondroitin sulfate, hyaluronic acid, dalconic acid, and salts thereof, mucopolysaccharides, heteropolysaccharides, and the like; , Poly (N-butylpyrrolidone), polyethylene glycol, polypropylene glycolone, polyacrylamide, etc .; synthetic organic polymer compounds; hydroxyethylcellulose, canoleboxy methinoresenorelose, methinoresenorelose, etc .; And the like.
- polysaccharides such as chondroitin sulfate, hyaluronic acid, dalconic acid, and salts thereof, mucopolysaccharides, heteropolysaccharides, and the like
- Poly (N-butylpyrrolidone) polyethylene glycol, polypropylene glycolone, polyacrylamide, etc .
- synthetic organic polymer compounds hydroxyethyl
- the ophthalmic composition according to the present invention includes glycyrrhizic acid and salts thereof, ⁇ -aminocaproic acid, allantoin in order to suppress intraocular inflammation caused by stress, wearing of contact lenses, and the like.
- An anti-inflammatory agent such as sodium azulene sulfonate, Tamine A (including retinol palmitate, rotini), vitamins B, B, B,
- Vitamin E such as d- ⁇ -tocopherol acetate, vitamins such as panthenol, and various kinds of amino acids such as aspartic acid and its salts, aminoethylsulfonic acid, arginine, alanine, lysine and daltamic acid
- Vitamin E such as d- ⁇ -tocopherol acetate
- vitamins such as panthenol
- amino acids such as aspartic acid and its salts, aminoethylsulfonic acid, arginine, alanine, lysine and daltamic acid
- the additive component can be appropriately added according to the intended use of the ophthalmic composition.
- the powerful ophthalmic composition according to the present invention is prepared by adding and containing the above-mentioned components in appropriate aqueous media in appropriate amounts in the same manner as in the prior art.
- Aqueous media used for this purpose include not only water itself such as tap water, purified water, and distilled water, but also physiological saline or sodium chloride-containing aqueous solution as long as it is a water-based solution, It goes without saying that known eye drops and contact lens solutions can be used.
- the ophthalmic composition according to the present invention obtained as described above has sufficient safety for the eyes, and is therefore advantageous as, for example, eye drops or liquid for contact lenses. It will be used for.
- Examples of vigorous contact lens liquids include, for example, a contact lens disinfectant, a contact lens cleaning liquid, a contact lens preservation liquid, a contact lens rinsing liquid, etc.
- Multi-purpose solutions such as washing and preservation solutions, washing and preservation rinse solutions, and sterilization and washing solutions that can be used.
- the ophthalmic composition according to the present invention when used as an eye drop and is prescribed for an eye having a symptom such as dry eye, it is the same as a conventionally known eye drop or eye drop. In addition, it is better if an appropriate amount is instilled, whereby symptoms such as discomfort in the eyes, dry feeling, blurred eyes, etc. are improved, and an excellent feeling in use can be realized.
- the specific hydroxypropylmethylcellulose contained according to the present invention does not have any adverse effect on the contact lens. There is no question as to whether or not there is.
- the eye drops brought into contact with the contact lens can effectively remove dirt such as eye oil and mucoid adhered to the surface of the contact lens, and at the same time, remove the surface of the lens outside the contour.
- the hydrophilicity of the lens is advantageously improved, and the occurrence of fogging and the like of the lens can be suppressed remarkably. Therefore, the feeling of dryness due to wearing of the contact lens, blurred vision, unstable visual acuity, foreign matter feeling, etc. Symptoms are effectively eliminated, and the feeling of wearing contact lenses can be dramatically improved.
- the contact lens removed from the eye is first treated with the ophthalmic composition according to the present invention. Cleaning and other care is performed by immersing the container in an appropriate filled container for a predetermined period of time. When the contact lens is worn again, the contact lens is taken out of the liquid and worn.
- dirt such as eye oil and mucoid adhering to the contact lens surface is advantageously removed by the specific hydroxypropylmethylcellulose described above.
- the type of contact lens to be used is not limited at all.
- Soft contact lenses and hard contact lenses which are classified as non-, low-, high-, etc., are all applicable, and any material, etc., of the contact lens may be asked when applying the present invention. There is no.
- ophthalmic compositions having a pH of 7.3 were prepared by adding predetermined components to sterilized purified water in various proportions as shown in Table 2 below (Comparative Examples 13 and 13, Examples 1) was prepared respectively.
- Table 2 Table 2 below
- Metrolose TC_5E or Metrolose 60SH-50 shown in Table 1 above was used as hydroxypropylmethylcellulose.
- Potassium sorbate was used as a preservative, and boric acid and borax were used as buffers.
- sodium chloride was used as an isotonic agent, and EDTA'2Na was used as a chelating agent.
- each volunteer was given an ophthalmic bottle containing 15 ml of the ophthalmic composition according to Comparative Examples 13 to 13 shown in Table 2, and the ophthalmic composition was used as an ophthalmic solution for one week. Used. After such use, volunteers themselves evaluated the difference in feeling of use of each ophthalmic composition during the test period, and tabulated the evaluations for each ophthalmic composition. The evaluation of the difference in feeling of use was based on items such as dry eyes, eye fatigue, eye spots, foreign body feeling when wearing the CL, dirt attached to the CL surface, a measuring L, and ground (clearness). It was implemented by taking a questionnaire.
- Comparative Example 1 Comparative Example 1 was about 10% better for the CL wearer, but the kinematic viscosity for the CL non-wearer was about 10% better. However, it was found that Comparative Example 1 with a lower value was superior by about 50%.
- each volunteer was handed an eye dropper bottle containing 7 ml of each of the ophthalmic compositions according to Comparative Example 1 and Example 1 shown in Table 2, and the ophthalmic composition was used as an eye drop, Used for one week.
- the volunteers themselves evaluated the difference in the feeling of use of each ophthalmic composition during the test period.
- the evaluation of the difference in feeling of use was based on questionnaires regarding items such as dry eyes, eye fatigue, eye spots, foreign body sensation when wearing the CL, dirt attached to the CL surface, and comfort (cleanness). By taking And implemented.
- the ophthalmic composition using the above can advantageously improve the effect of removing such stains as compared with the one using hydroxypropylmethylcellulose having a molecular weight equal to or higher than the entanglement critical molecular weight. This is thought to be because hydroxypropyl methylcellulose molecular force does not cause entanglement between molecules, and penetrates dirt adhering to the cornea or anterior eye and contact lenses as a single molecule and acts effectively. It is.
- hydroxypropyl methylcellulose having a molecular weight less than the entanglement critical molecular weight is contained, and at 20 ° C. Since the kinematic viscosity is 2 mm 2 / s or less, the entanglement force between hydroxypropylmethylcellulose molecules in the ophthalmic composition is extremely effectively prevented, whereby the hydroxypropylmethylcellulose molecules are contained in the ophthalmic composition. Can freely move, and the surfactant effect of the hydroxypropylmethylcellulose molecule can be advantageously exhibited without any hindrance, such as eye oil and mucoid adhering to the cornea or extracontour lens. It is possible to effectively remove dirt. For this reason, various symptoms such as blurred eyes, distortion of an image, a feeling of dryness, and a feeling of foreign matter caused by the adhesion of dirt can be more advantageously prevented than in the past. -ing
- the ophthalmic composition according to the present invention may be a conventional ophthalmic composition (for example, artificial tears) in which entanglement of hydroxypropylmethylcellulose molecules is not taken into consideration, or a thickening agent such as hydroxypropylmethylcellulose. Compared to artificial tears and the like that are not blended, it is extremely effective in improving the usability, the comfort of wearing, and the feeling of wearing contact lenses.
- FIG. 1 is a logarithmic graph showing the relationship between the kinematic viscosity and the weight average molecular weight of a 3 w / w% aqueous solution of hydroxypropylmethylcellulose at 20 ° C.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Eyeglasses (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04730634A EP1623722B1 (en) | 2003-05-15 | 2004-04-30 | Composition for ophthalmic use |
AT04730634T ATE471723T1 (de) | 2003-05-15 | 2004-04-30 | Zusammensetzung zur ophthalmischen verwendung |
JP2005506159A JP4739022B2 (ja) | 2003-05-15 | 2004-04-30 | 眼科用組成物 |
DE602004027800T DE602004027800D1 (de) | 2003-05-15 | 2004-04-30 | Zusammensetzung zur ophthalmischen verwendung |
US11/265,130 US20060052340A1 (en) | 2003-05-15 | 2005-11-02 | Ophthalmic solution |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-137828 | 2003-05-15 | ||
JP2003137828 | 2003-05-15 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/265,130 Continuation US20060052340A1 (en) | 2003-05-15 | 2005-11-02 | Ophthalmic solution |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004100993A1 true WO2004100993A1 (ja) | 2004-11-25 |
Family
ID=33447269
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/005837 WO2004100993A1 (ja) | 2003-05-15 | 2004-04-30 | 眼科用組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20060052340A1 (ja) |
EP (1) | EP1623722B1 (ja) |
JP (1) | JP4739022B2 (ja) |
AT (1) | ATE471723T1 (ja) |
DE (1) | DE602004027800D1 (ja) |
WO (1) | WO2004100993A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008152705A1 (ja) * | 2007-06-13 | 2008-12-18 | Menicon Co., Ltd. | コンタクトレンズ用洗浄シート |
JP2009096790A (ja) * | 2007-09-28 | 2009-05-07 | Rohto Pharmaceut Co Ltd | 疲れ目改善用及び/又はかすみ目改善用コンタクトレンズ装着液 |
JP2012198538A (ja) * | 2012-03-12 | 2012-10-18 | Menicon Co Ltd | コンタクトレンズ用組成物 |
JP5731046B1 (ja) * | 2014-05-30 | 2015-06-10 | 株式会社メニコン | コンタクトレンズ用組成物 |
WO2016117515A1 (ja) * | 2015-01-21 | 2016-07-28 | クオリカプス株式会社 | インク及びこれを用いた可食体の製造方法並びに可食体の印刷方法 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009048929A1 (en) * | 2007-10-08 | 2009-04-16 | Lux Biosciences, Inc. | Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors |
WO2010086989A1 (ja) | 2009-01-29 | 2010-08-05 | 日東電工株式会社 | 口腔内フィルム状基剤及び製剤 |
WO2010096558A1 (en) * | 2009-02-18 | 2010-08-26 | Eyeon Particle Sciences Llc | Bi-functional co-polymer use for ophthalmic and other topical and local applications |
CN102458370A (zh) * | 2009-06-09 | 2012-05-16 | 卢克斯生物科技公司 | 用于眼科用途的表面药物递送*** |
WO2011022736A1 (en) * | 2009-08-21 | 2011-02-24 | Belkin International, Inc. | Entertainment control system and related methods |
WO2011057275A2 (en) * | 2009-11-09 | 2011-05-12 | Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University | Molecular films for hydrophobic implant surfaces |
JP5751868B2 (ja) | 2010-03-30 | 2015-07-22 | 日東電工株式会社 | フィルム状製剤及びその製造方法 |
JP2011207847A (ja) * | 2010-03-30 | 2011-10-20 | Nitto Denko Corp | フィルム状製剤及びその製造方法 |
JP5841433B2 (ja) | 2012-01-11 | 2016-01-13 | 日東電工株式会社 | 口腔内フィルム状基剤及び製剤 |
JP2016501931A (ja) | 2012-11-21 | 2016-01-21 | ユニバーシティー オブ ルイヴィル リサーチ ファウンデーション,インコーポレーテッドUniversity Of Louisville Research Foundation,Inc. | 酸化的損傷を減じるための組成物および方法 |
EP3256136A4 (en) | 2015-02-09 | 2018-11-21 | University Of Louisville Research Foundation, Inc. | Ophthalmic compositions and methods for reducing oxidative damage to an eye lens |
WO2018009177A1 (en) | 2016-07-06 | 2018-01-11 | Eyeon Particle Sciences Llc | Bi-functional co-polymer use for ophthalmic and other topical and local applications |
US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999016447A1 (fr) * | 1997-09-26 | 1999-04-08 | Wakamoto Pharmaceutical Co., Ltd. | Preparation aqueuse contenant un agent antiviral a ossature purine ou pyrimidine |
JP2001318348A (ja) * | 2000-05-11 | 2001-11-16 | Lion Corp | コンタクトレンズ装着液 |
JP2002322048A (ja) * | 2001-04-24 | 2002-11-08 | Lion Corp | ソフトコンタクトレンズ用組成物 |
JP2003055262A (ja) * | 1997-05-14 | 2003-02-26 | Senju Pharmaceut Co Ltd | 再分散性の良い水性懸濁液剤 |
JP2003183157A (ja) * | 2001-12-19 | 2003-07-03 | Lion Corp | 眼科用組成物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5599534A (en) * | 1994-08-09 | 1997-02-04 | University Of Nebraska | Reversible gel-forming composition for sustained delivery of bio-affecting substances, and method of use |
JP4848575B2 (ja) * | 2000-03-30 | 2011-12-28 | ゼリア新薬工業株式会社 | アラントインを配合した安定な液剤 |
AR034200A1 (es) * | 2001-01-12 | 2004-02-04 | Novartis Ag | Agente para el cuidado de lentes de contacto, su uso, y procedimiento de limpieza |
-
2004
- 2004-04-30 AT AT04730634T patent/ATE471723T1/de not_active IP Right Cessation
- 2004-04-30 WO PCT/JP2004/005837 patent/WO2004100993A1/ja active Application Filing
- 2004-04-30 EP EP04730634A patent/EP1623722B1/en not_active Expired - Lifetime
- 2004-04-30 DE DE602004027800T patent/DE602004027800D1/de not_active Expired - Lifetime
- 2004-04-30 JP JP2005506159A patent/JP4739022B2/ja not_active Expired - Lifetime
-
2005
- 2005-11-02 US US11/265,130 patent/US20060052340A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003055262A (ja) * | 1997-05-14 | 2003-02-26 | Senju Pharmaceut Co Ltd | 再分散性の良い水性懸濁液剤 |
WO1999016447A1 (fr) * | 1997-09-26 | 1999-04-08 | Wakamoto Pharmaceutical Co., Ltd. | Preparation aqueuse contenant un agent antiviral a ossature purine ou pyrimidine |
JP2001318348A (ja) * | 2000-05-11 | 2001-11-16 | Lion Corp | コンタクトレンズ装着液 |
JP2002322048A (ja) * | 2001-04-24 | 2002-11-08 | Lion Corp | ソフトコンタクトレンズ用組成物 |
JP2003183157A (ja) * | 2001-12-19 | 2003-07-03 | Lion Corp | 眼科用組成物 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008152705A1 (ja) * | 2007-06-13 | 2008-12-18 | Menicon Co., Ltd. | コンタクトレンズ用洗浄シート |
JP2009096790A (ja) * | 2007-09-28 | 2009-05-07 | Rohto Pharmaceut Co Ltd | 疲れ目改善用及び/又はかすみ目改善用コンタクトレンズ装着液 |
JP2012198538A (ja) * | 2012-03-12 | 2012-10-18 | Menicon Co Ltd | コンタクトレンズ用組成物 |
JP5731046B1 (ja) * | 2014-05-30 | 2015-06-10 | 株式会社メニコン | コンタクトレンズ用組成物 |
WO2016117515A1 (ja) * | 2015-01-21 | 2016-07-28 | クオリカプス株式会社 | インク及びこれを用いた可食体の製造方法並びに可食体の印刷方法 |
JPWO2016117515A1 (ja) * | 2015-01-21 | 2017-08-17 | クオリカプス株式会社 | インク及びこれを用いた可食体の製造方法並びに可食体の印刷方法 |
JP2018141160A (ja) * | 2015-01-21 | 2018-09-13 | クオリカプス株式会社 | インク及びこれを用いた可食体の製造方法並びに可食体の印刷方法 |
JP2019014912A (ja) * | 2015-01-21 | 2019-01-31 | クオリカプス株式会社 | インク及びこれを用いた可食体の製造方法並びに可食体の印刷方法 |
Also Published As
Publication number | Publication date |
---|---|
ATE471723T1 (de) | 2010-07-15 |
EP1623722B1 (en) | 2010-06-23 |
DE602004027800D1 (de) | 2010-08-05 |
JP4739022B2 (ja) | 2011-08-03 |
JPWO2004100993A1 (ja) | 2006-07-13 |
US20060052340A1 (en) | 2006-03-09 |
EP1623722A1 (en) | 2006-02-08 |
EP1623722A4 (en) | 2007-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060052340A1 (en) | Ophthalmic solution | |
JP5078254B2 (ja) | 眼科用組成物 | |
EP1165731A1 (en) | A viscosity enhanced ophthalmic solution, having a detergent action on contact lenses | |
US20060035842A1 (en) | Ophthalmic composition | |
AU2014209426B2 (en) | Poly(nitrogen/amine) derivatives of a natural wax and ophthalmic compositions | |
JP3142842B1 (ja) | 眼科用組成物及びソフトコンタクトレンズへの吸着抑制方法 | |
JP4850513B2 (ja) | 点眼用組成物 | |
JP2020128437A (ja) | シリコーンハイドロゲルコンタクトレンズ用眼科組成物 | |
EP1845405A1 (en) | Liquid agent composition for contact lens | |
KR101726029B1 (ko) | 알콕실화된 천연 왁스를 갖는 안과용 조성물 | |
JP5678530B2 (ja) | ソフトコンタクトレンズ用眼科組成物 | |
JP2005008568A (ja) | 眼科用組成物 | |
JP5587359B2 (ja) | コンタクトレンズ用組成物 | |
JP4981181B1 (ja) | コンタクトレンズ用組成物 | |
JP2006000170A (ja) | コンタクトレンズ用組成物 | |
JP4646807B2 (ja) | 眼科用組成物 | |
WO2005023283A1 (ja) | 眼科用組成物 | |
JP4832636B2 (ja) | 眼科用組成物 | |
JP5080418B2 (ja) | コンタクトレンズ用溶液 | |
JP2018118964A (ja) | 眼科組成物 | |
WO2004082673A1 (ja) | 眼科用液剤組成物 | |
JP2002003404A (ja) | 粘膜洗浄用組成物及び洗浄方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005506159 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11265130 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004730634 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004730634 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11265130 Country of ref document: US |